Healthcare - Biotechnology - NASDAQ - US
$ 1.36
-6.85 %
$ 6.09 M
Market Cap
-0.01
P/E
INCOME STATEMENT
0
REVENUE
-9.94 M
OPERATING INCOME
-9.95 M
NET INCOME
EFFICIENCY
Earnings Waterfall
Alzamend Neuro, Inc.
| Revenue | 0 |
| Cost Of Revenue | 50.7 K |
| Gross Profit | -50.7 K |
| Operating Expenses | 9.94 M |
| Operating Income | -9.94 M |
| Other Expenses | 10.1 K |
| Net Income | -9.95 M |
Income Statement
Millions
| Apr-2024 | Apr-2023 | Apr-2022 | Apr-2021 | Apr-2020 | Apr-2019 | Apr-2018 | Apr-2017 | Apr-2016 | |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GROSS PROFIT | |||||||||
| Cost Of Revenue | 50.7 K | 23.1 K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 50.7 K | 23.1 K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| OPERATING INCOME | |||||||||
| Operating Expenses | 9.9 | 14.9 | 12.3 | 5.0 | 4.4 | 5.0 | 0.9 | 1.5 | 69.5 K |
| Selling, General and Administrative Expenses | 3.5 | 7.4 | 7.1 | 3.6 | 3.4 | 1.3 | 0.6 | 1.3 | 69.5 K |
| Research and Development Expenses | 6.5 | 7.4 | 5.2 | 1.3 | 1.1 | 3.7 | 0.3 | 0.3 | 0 |
| Operating Income | (9.9) | (14.9) | (12.3) | (5.0) | (4.4) | (5.0) | (0.9) | (1.5) | 69.5 K |
| PRE-TAX INCOME | |||||||||
| Interest Income Expense | 10.1 K | 7.7 K | 46.5 K | 0.2 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income | 10.1 K | 7.7 K | 42.5 K | 94.7 K | 13.9 K | 0.1 | 33.2 K | 21.5 K | 0 |
| Pre-Tax Income | (9.9) | (14.9) | (12.4) | (5.0) | (4.4) | (4.9) | (0.9) | (1.6) | 69.5 K |
| NET INCOME | |||||||||
| Tax Provision | 0 | (0.1) | 42.5 K | 0.2 | 13.9 K | (0.1) | (0.9) | 21.5 K | 0 |
| Net Income | (9.9) | (14.9) | (12.4) | (5.2) | (4.4) | (4.9) | (0.9) | (1.6) | 69.5 K |
| EPS | 14.7 | 22.9 | 20.9 | 10.8 | 9.26 | 12.4 | 1.64 | 8.18 | 0.421 |